exemestane vs fulvestrant | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
clinical benefit | 1.00 [0.71 1.41] | p=1.00 | 0 | 693 | 1 | Chia, | objective response (ORR) | 1.08 [0.56 2.08] | p=1.00 | 0 | 693 | 1 | Chia, | progression or death (progression free survival PFS) | 1.04 [0.52 2.07] | p=1.00 | 0 | -18 | 1 | Chia, | hot flushes | 1.29 [0.79 2.12] | p=1.00 | 0 | 693 | 1 | Chia, | rash | no data | vaginal bleeding | no data | thromboembolic AE | no data | arthralgia | no data | vomiting | no data | diarrhoea | 0.86 [0.36 2.01] | p=1.00 | 0 | 693 | 1 | Chia, | nausea | 1.15 [0.65 2.04] | p=1.00 | 0 | 693 | 1 | Chia, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
exemestane vs megestrol acetate | No demonstrated result hot flushes by 151% (harmful effect) vomiting by 272% (harmful effect) nausea by 84% (harmful effect) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
clinical benefit | 0.92 [0.69 1.24] | p=1.00 | 0 | 769 | 1 | Kaufmann, | objective response (ORR) | 0.83 [0.55 1.25] | p=1.00 | 0 | 769 | 1 | Kaufmann, | death (overall survival) | 0.85 [0.49 1.48] | p=1.00 | 0 | -18 | 1 | Kaufmann, | progression or death (progression free survival PFS) | 0.82 [0.46 1.45] | p=1.00 | 0 | -18 | 1 | Kaufmann, | hot flushes | 2.51 [1.45 4.35] | p=0.04 | 0 | 758 | 1 | Kaufmann, | vaginal bleeding | no data | thromboembolic AE | no data | arthralgia | no data | rash | 16.76 [0.95 294.52] | p=1.00 | 0 | 758 | 1 | Kaufmann, | vomiting | 3.72 [1.02 13.64] | p=0.04 | 0 | 758 | 1 | Kaufmann, | diarrhoea | no data | nausea | 1.84 [1.04 3.28] | p=0.04 | 0 | 758 | 1 | Kaufmann, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
exemestane vs tamoxifen | No demonstrated result suggested objective response (ORR) by 59% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
clinical benefit | 0.74 [0.36 1.51] | p=1.00 | 0 | 122 | 1 | Paridaens, | objective response (ORR) | 0.41 [0.18 0.96] | p=0.04 | 0 | 122 | 1 | Paridaens, | rash | no data | vaginal bleeding | no data | thromboembolic AE | no data | hot flushes | 0.79 [0.38 1.62] | p=1.00 | 0 | 121 | 1 | Paridaens, | arthralgia | 1.74 [0.60 5.07] | p=1.00 | 0 | 121 | 1 | Paridaens, | vomiting | no data | diarrhoea | no data | nausea | 0.63 [0.29 1.41] | p=1.00 | 0 | 121 | 1 | Paridaens, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |